12 completed, 3 unknown, 2 withdrawn, 1 terminated. 7 Phase 4, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Completed 4, Withdrawn 2, Unknown 1 |
| Early Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow iopromide: new trials by email Literature Review of iopromide trials Research Report on iopromide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low-acid Contrast Media for Preventing Post ERCP Pancreatitis Ioversol, Iopromide, Iohexol - Post-ERCP Acute Pancreatitis | Completed | Shandong University | 3979 | 2025-08-01 | 2026-02-06 | |
| Serum Thyroid Function After Iodinated Contrast Administration Iodinated contrast agents - Thyroid Dysfunction | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 400 | 2023-02-15 | 2023-05-30 | |
| Pediatric Risk of Hypothyroidism With Iodinated Contrast Media Iohexol, Iodixanol, Iopromide - Hypothyroidism | Phase 4 | Withdrawn | GE Healthcare | 2022-03-01 | 2022-04-20 | |
| Study on the Risk of Allergy-like Reactions After Intra-arterial or Intra-venous Injection of the Marketed X-ray Contrast Medium Iopromid Iopromide (Ultravist, BAY86-4877) - Contrast Medium | Completed | Bayer | 133331 | 2018-10-12 | 2020-02-17 | |
| VOLtage-based Contrast Media AdaptatioN in Coronary Computed Tomography Angiography Ultravist 370Mg I/Ml Solution for Injection - Coronary Artery Disease, Cardiovascular Diseases | Completed | Medical University of South Carolina | 120 | 2017-03-22 | 2020-02-13 | |
| A Non-interventional Study to Observe the Computed Tomographic Angiography Image Quality With Different Contrast Media Injection Protocols Under Different Computed Tomography Machines Parameters Setting Iopromide (Ultravist, BAY86-4877) - Angiography, Multidetector Computed Tomography | Completed | Bayer | 1214 | 2016-07-26 | 2018-10-02 | |
| An Early Phase Clinical Trial to Evaluate the Feasibility of CEST MRI in Patients With Early Stage Breast Cancer CEST MRI - Breast Cancer | Early Phase 1 | Terminated | University of Arizona | 8 | 2014-08-01 | 2016-10-27 |
| Role of Perfusion CT in Pancreatic Cancer iopromide, CT - Adenocarcinoma, Pancreas, Neuroendocrine Carcinoma of Pancreas | Unknown | Seoul National University Hospital | 48 | 2012-11-01 | 2020-10-08 | |
| Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction iodixanol, iopromide - Kidney Failure, Chronic | Phase 4 | Unknown | Yong Huo | 200 | 2012-04-01 | 2013-10-16 |
| Observational Study of Ultravist in Patients Requiring CECT Iopromide (Ultravist, BAY86-4877) - Diagnostic Imaging | Completed | Bayer | 11660 | 2011-09-01 | 2015-01-21 | |
| Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography iobitridol, iopromide, iomeprol - Coronary Artery Disease | Phase 4 | Completed | Guerbet | 468 | 2010-11-01 | 2015-12-16 |
| The Safety and toleRability of UltraviSt in Patients Undergoing Cardiac CaTheterization (TRUST) Iopromide (Ultravist, BAY86-4877) - Angiocardiography | Completed | Bayer | 17513 | 2010-08-01 | 2013-06-11 | |
| A Safety Comparison of Iopromide and Iodixanol in Renal Impaired Patients Iopromide (Ultravist), Iodixanol (Visipaque) - Kidney Failure, Chronic | Phase 4 | Completed | Chinese PLA General Hospital | 592 | 2009-02-01 | 2011-06-27 |
| Contrast-medium Induced Nephrotoxicity in Patients Undergoing Coronary Angiography - Iodixanol Versus Iopromide contrast agent (iopromide), contrast agent (iodixanol) - Chronic Renal Insufficiency, Coronary Angiography | Phase 4 | Completed | Seoul National University Bundang Hospital | 420 | 2009-02-01 | 2010-07-07 |
| Comparison Between Iso-Osmolar and Ipo-Osmolar Contrast Agents in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary Percutaneous Coronary Intervention (PCI) Iodixanol, Iopromide - Contrast Induced Nephropathy, Acute Myocardial Infarction | Phase 4 | Completed | Ospedale San Donato | 432 | 2008-12-01 | 2010-11-16 |
| PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination Ultravist (Iopromide, BAY86-4877) - Diagnostic Imaging | Completed | Bayer | 44920 | 2008-03-01 | 2011-02-28 | |
| Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography Iodixanol, Ioversol, Iopromide - Coronary Artery Disease (CAD), Renal Impairment | Phase 4 | Withdrawn | GE Healthcare | 2006-06-01 | 2019-04-29 | |
| Ultravist: Safety and Efficacy in Computed Tomography of Head and Body Iopromide 370 mg I/mL, Iopromide 300 mg I/mL - Computed Tomography, Diagnostic Imaging | Phase 3 | Completed | Bayer | 435 | 2005-10-01 | 2014-02-28 |
Coronary Artery Disease (3) · Kidney Failure, Chronic (2) · Renal Insufficiency, Chronic (2) · Adenocarcinoma (1) · Breast Neoplasms (1) · Cardiovascular Diseases (1) · Diabetes Mellitus (1) · Hypothyroidism (1) · Renal Insufficiency (1)
Bayer (6) · GE Healthcare (2) · Chinese PLA General Hospital (1) · Guerbet (1) · Medical University of South Carolina (1) · Ospedale San Donato (1) · Seoul National University Bundang Hospital (1) · Seoul National University Hospital (1) · Shandong University (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · University of Arizona (1) · Yong Huo (1)
China (8) · Germany (4) · South Korea (4) · United States (4) · Italy (3) · Bosnia and Herzegovina (1) · Colombia (1) · France (1) · Hungary (1) · India (1) · Indonesia (1) · Iran (1) · Malaysia (1) · Moldova (1) · Pakistan (1)
Jeong Min Lee, MD, PhD (1) · Johnny Gibbs, Jr., CCRA (1) · Leonardo Bolognese, MD, FESC (1) · Li Yan (1) · Marc Pignot, PhD (1) · Paul F. Sherwin, MD, PhD (1) · Pavani Chalasani, MD (1) · Philippe Bourrinet, PharmD (1) · Tae-Jin Youn, MD, PhD (1) · Yundai Chen, MD (1) · Zuzana Jirakova Trnkova, MD, PhD (1)